Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephan Stilgenbauer

Showing results (281-290 of 466) with videos related to

Pageof 47
Sort By:
American Journal of Hematology|April 5, 2024
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trialPaula Cramer, Julia von Tresckow, Anna-Maria Fink, et al.
International Journal of Cancer|July 11, 2007
Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemiaBirgit Kainz, Medhat Shehata, Martin Bilban, et al.
Blood|February 26, 2013
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trialPeter Dreger, Andrea Schnaiter, Thorsten Zenz, et al.
British Journal of Haematology|July 9, 2016
Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trialAnnika Scheffold, Billy Michael Chelliah Jebaraj, Sonia Jaramillo, et al.
Journal of Reproductive Immunology|February 19, 2025
Future perspectives of fertility protectionKarin Bundschu, Silviya Aleksandrova-Yankulovska, Christian Denzer, et al.
Leukemia|June 25, 2022
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trialJulia von Tresckow, Paula Cramer, Sandra Robrecht, et al.
Blood|March 16, 2018
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLMichael Hallek, Bruce D Cheson, Daniel Catovsky, et al.
Leukemia|December 21, 2018
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemiaJulia von Tresckow, Paula Cramer, Jasmin Bahlo, et al.
American Journal of Hematology|November 15, 2021
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapyRelja Popovic, Fengjiao Dunbar, Charles Lu, et al.
British Journal of Haematology|July 1, 2014
Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approachG Doreen Te Raa, Jitka Malčiková, Marek Mraz, et al.
Pageof 47

Showing results (281-290 of 466) with videos related to

Sort By:
Pageof 47
American Journal of Hematology|April 5, 2024
Bendamustine, followed by obinutuzumab and idelalisib in chronic lymphocytic leukemia (CLL2-BCG): Final analysis of a multicenter, open-label phase-II-trialPaula Cramer, Julia von Tresckow, Anna-Maria Fink, et al.
International Journal of Cancer|July 11, 2007
Overexpression of the paternally expressed gene 10 (PEG10) from the imprinted locus on chromosome 7q21 in high-risk B-cell chronic lymphocytic leukemiaBirgit Kainz, Medhat Shehata, Martin Bilban, et al.
Blood|February 26, 2013
TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trialPeter Dreger, Andrea Schnaiter, Thorsten Zenz, et al.
British Journal of Haematology|July 9, 2016
Impact of telomere length on the outcome of allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukaemia: results from the GCLLSG CLL3X trialAnnika Scheffold, Billy Michael Chelliah Jebaraj, Sonia Jaramillo, et al.
Journal of Reproductive Immunology|February 19, 2025
Future perspectives of fertility protectionKarin Bundschu, Silviya Aleksandrova-Yankulovska, Christian Denzer, et al.
Leukemia|June 25, 2022
Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trialJulia von Tresckow, Paula Cramer, Sandra Robrecht, et al.
Blood|March 16, 2018
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLLMichael Hallek, Bruce D Cheson, Daniel Catovsky, et al.
Leukemia|December 21, 2018
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemiaJulia von Tresckow, Paula Cramer, Jasmin Bahlo, et al.
American Journal of Hematology|November 15, 2021
Identification of recurrent genomic alterations in the apoptotic machinery in chronic lymphocytic leukemia patients treated with venetoclax monotherapyRelja Popovic, Fengjiao Dunbar, Charles Lu, et al.
British Journal of Haematology|July 1, 2014
Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approachG Doreen Te Raa, Jitka Malčiková, Marek Mraz, et al.
Pageof 47